



LUND UNIVERSITY

Molecular microheterogeneity of prostate specific antigen in seminal fluid by mass spectrometry.

Végvári, Ákos; Rezeli, Melinda; Sihlbom, Carina; Häkkinen, Jari; Carlsohn, Elisabet; Malm, Johan; Lilja, Hans; Laurell, Thomas; Marko-Varga, György

Published in:
Clinical Biochemistry

DOI:
[10.1016/j.clinbiochem.2011.11.018](https://doi.org/10.1016/j.clinbiochem.2011.11.018)

2012

[Link to publication](#)

Citation for published version (APA):

Végvári, Á., Rezeli, M., Sihlbom, C., Häkkinen, J., Carlsohn, E., Malm, J., Lilja, H., Laurell, T., & Marko-Varga, G. (2012). Molecular microheterogeneity of prostate specific antigen in seminal fluid by mass spectrometry. *Clinical Biochemistry*, 45(4-5), 331-338. <https://doi.org/10.1016/j.clinbiochem.2011.11.018>

Total number of authors:
9

General rights

Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

Molecular Microheterogeneity of Prostate Specific Antigen in Seminal Fluid by Mass Spectrometry

Ákos Végvári¹, Melinda Rezeli¹, Carina Sihlbom², Jari Häkkinen³, Elisabet Carlsohn², Johan Malm⁴, Hans Lilja^{4,5}, Thomas Laurell^{1,6} György Marko-Varga¹

Addresses:

¹Clinical Protein Science & Imaging, Dept. of Measurement Technology and Industrial Electrical Engineering, Lund University, BMC C13, SE-221 84 Lund, Sweden

²Proteomics Core Facility, Göteborg University, Medicinaregatan 7, SE-413 90 Göteborg, Sweden

³Dept. of Oncology, Clinical Sciences, Lund University and Skåne University Hospital, Barngatan 2B, SE-221 85 Lund, Sweden

⁴Dept. of Laboratory Medicine, Section for Clinical Chemistry, Lund University, Skåne University Hospital in Malmö, SE-205 02 Malmö, Sweden

⁵Depts. of Clinical Laboratories, Surgery (Urology), and Medicine (GU-Oncology), Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA

⁶Dept. Biomedical Engineering, Dongguk University, Seoul, Republic of Korea

Corresponding author: Ákos Végvári

Clinical Protein Science & Imaging, Dept. of Measurement Technology and Industrial Electrical Engineering, Lund University, BMC C13, SE-221 84 Lund, Sweden

Phone: +46-46-222 3721

Fax: +46-46-222 4527

Email: akos.vegvari@elmat.lth.se

Abstract

Objectives: Prostate specific antigen (PSA) is a widely used and clinically valuable marker for prostate disease. In order to enable the development of new PSA assays and progress the understanding of the biology of PSA we have analyzed PSA in seminal plasma.

Design and Methods: PSA in seminal plasma from men attending a fertility clinic and healthy controls was analyzed using SDS-PAGE, Western blotting and mass spectrometry.

Results: Using mass spectrometry, different forms of PSA could be identified in 1-9 bands seen on SDS-PAGE analysis of the respective sample. However, a majority of these molecular forms of PSA were not observed on Western blots. Enzymatic activity of PSA isoforms was demonstrated by sequencing data in zymogram gels. Multivariate analysis of clinical data revealed well-separated patient groups.

Conclusions: We demonstrated that PSA in seminal plasma occurs in several isoforms, yet not all were detectable using an antibody based clinical routine method. The heterogeneity of PSA expression might be of clinical significance, by an improved patient phenotyping.

Keywords: prostate specific antigen, isoform, seminal plasma, infertility, MALDI LTQ Orbitrap XL, ESI-LTQ FT-ICR

1. Introduction

Prostate cancer is the most common cancer in Sweden (8,870 new cases in 2007) accounting for approximately one third of all cancer diagnoses among men (Socialstyrelsens Cancerregistret 2009, <http://www.roc.se/cancerreg.asp>). The worldwide prevalence is increasing and approximately one out of six men will be diagnosed with prostate cancer. The clinical course of the disease varies and the majority of the patients will eventually die of other causes than prostate cancer. Quantitative analysis of the prostate specific antigen (PSA) in plasma is a cornerstone both for diagnosing and monitoring the disease [1; 2]. Approximately, 25 million PSA tests were performed worldwide in 2005 (Clinical Data, Inc., Newton, MA, <http://www.clda.com>).

Although, PSA is the clinically most valuable tumor marker used, it is associated with considerable specificity and sensitivity problems. Increased PSA values can result from malignant as well as benign prostate disease, *e.g.*, hyperplasia or prostatitis. Consequently, 65-75% of men who undergo a prostate biopsy due to a moderate PSA elevation ($\approx 3-10$ ng/mL, ref. value <3 ng/mL) do not have evidence of cancer [3; 4] and 25% of men with PCa have normal PSA levels [5].

To improve the specificity, two molecular forms of PSA are routinely analyzed: free PSA (fPSA) and total PSA (tPSA = the sum of fPSA and PSA in complex with α_1 -antichymotrypsin, SERPINA3). The level of fPSA is lower in men with malignant disease than in men with benign hyperplasia. Yet, there is no clear-cut method to distinguish the various forms of prostate disease.

In order to improve its clinical value, new immunoassays for different molecular forms of PSA, *e.g.*, pro-PSA, intact PSA and BPSA (a PSA variant internally cleaved

at Lys182/Ser183 [6; 7]) have been developed but so far no substantial increment in diagnostic accuracy compared to analysis of tPSA and fPSA [8] has been demonstrated.

PSA is a serine protease produced by the epithelial cells of the prostate and secreted as an inactive proenzyme (proPSA) into seminal fluid [4; 9], where it can be activated by the kallikrein-related peptidase 2 (hK2) and other endopeptidases of the prostate [4; 10-12]. PSA has restricted chymotrypsin-like endoproteolytic activity, cleaving its biological substrates, semenogelin 1 and 2 (SEMG1; SEMG2) [13; 14], and fibronectin [13], as well as laminin and gelatin [15]. PSA in seminal fluid occurs predominantly in an active single-chain form. A minor fraction is inactivated due to internal cleavages [9; 12] or complex formation with the protein C inhibitor (SERPINA5), released from the seminal vesicles [16-18]. Furthermore, it has been demonstrated that fPSA displays a considerable structural heterogeneity in serum, seminal plasma, and hyperplastic or cancerous tissue [19]. It has been also recently reported that men with male factor infertility have an increased risk of subsequently developing aggressive high-grade prostate cancer [20]. For this reason, it has been suggested that male infertility may be an early and identifiable risk factor for the development of clinically significant prostate cancer.

Posttranslational modifications of the PSA molecule also contribute to the structural heterogeneity. PSA is a glycoprotein composed of approx. 8% *N*-linked carbohydrate [21], a biantennary *N*-linked oligosaccharide of the *N*-acetyllactosamine type with terminal sialic acid groups [22]. PSA in seminal fluid displays large heterogeneity mainly because of a variable degree of sialylation [23]. It has been shown that the carbohydrate side chains differ greatly in plasma

and seminal fluid in PCa patients [24]. Contributing to the heterogeneity of the PSA molecule there are also differences in primary structure, carbohydrate composition and enzymatic activity [7; 23; 25-30].

Exactly which molecular form(s) of PSA the different commercially available clinical routine assays measure has not been fully elucidated. Differences in the composition of the PSA molecular forms could reflect diversity in the biology of prostate disease, which might be of diagnostic value.

We have previously presented a strategy, that the combination of analytical principles can improve the resolving power of PSA identification, complementarily utilizing 1-D gel electrophoresis and high resolution MALDI-MS, which could confirm complex patterns of PSA forms in seminal plasma [31]. In the present study we have applied these technology platforms, in addition with clinical data, to characterize the expressed molecular forms of PSA in seminal plasma. Thirty-four participants were enrolled in this study with both healthy controls and patients, *i.e.*, men being diagnosed for infertility. Our study objective was to employ modern proteomic tools to characterize different expression of PSA variants in seminal fluid. Taking into consideration the recent reports on the disease link between male infertility and prostate cancer [20], the study outcome opens up for functional interpretations related to PSA isoform expression patterns and clinical demography.

2. Material and Methods

2.1. Seminal plasma

Semen samples were obtained from young men undergoing investigation for infertility prior to final diagnosis of disorders and healthy volunteers. Seminal plasma was provided by the Center for Reproductive Medicine at Malmö University Hospital, following the guidelines of the Helsinki Declaration. The collection of seminal plasma was approved by the ethical board at Lund University (approval number: LU 532-03) and the samples were processed according to the WHO guidelines (WHO, 1999). Seminal plasma was prepared by centrifugation at 10,000 *g* for 10 min and stored at -20°C until use. **Table 1** gives details on the clinical data from the participating subjects in the study. Free PSA (fPSA) ranged between 0.233 and 1.915 mg/mL (see **Table 1**) as determined by the DELFIA assay (Perkin Elmer, Turku, Finland) [32]. The total protein content of seminal plasma samples was determined using Bradford reagent (Sigma, Steinheim, Germany) and equal amounts of protein (88 µg) were applied on gels. The semen volumes are aligned with age matching and the PSA levels measured by ELISA (DELIFIA). In addition, we analyzed the fructose levels, because patients with obstruction or aplasia of vas deferens have typically low fructose concentrations. Clinical implication of impaired prostate function is often associated with low zinc levels, whereas the inflammatory status represented by various inflammatory processes (*e.g.*, prostatitis) results in an increased albumin level. Correspondingly, PSA, fructose, zinc and albumin assays were completed and these data are presented in **Table 1**.

2.2. Gel electrophoresis techniques

PSA expression was detected by SDS-PAGE gel electrophoresis in 0.75 mm thick, 12 %T, 2.67 %C polyacrylamide gels under reducing conditions. The samples were reduced with 4 mM DL-dithiothreitol while boiled for 5 minutes and alkylated by addition of 2 μ L of 0.5 M iodoacetamide at room temperature for 15 min. Following preparation 10 μ L of samples and 3 μ L of protein molecular weight standards (PageRuler™ Prestained Protein Ladder Plus from Fermentas, St. Leon-Rot, Germany) were loaded. The gels were run at a constant voltage of 125 V for 1 h 10 min in a MiniProtean III electrophoresis unit (Bio-Rad, Hercules, CA). Staining was performed with Coomassie blue R350 (GE Healthcare, Uppsala, Sweden) for 1 h according to the manufacturer's recommendations.

The Western blot analysis was performed using 0.75 mm thick, 12 %T, 2.67 %C polyacrylamide gels run at non-reducing conditions. The separated protein bands were transferred onto PVDF membranes (0.45 pore size Invitrolon™ PVDF, Invitrogen, Carlsbad, CA) using a tank blotting (Bio-Rad, Hercules, CA) at constant current (350 mA) for 1.5 h. The membranes were blocked with 1% of BSA in 50 mM Tris-HCl/150 mM NaCl/0.1% Tween-20, pH 7.4. The primary antibodies (2E9) [33] were used at 1:5000 dilution. The secondary antibody of ECL anti-mouse IgG (used at 1:10000 dilution) and the horseradish peroxidase reagent system (ECL) were purchased from GE Healthcare (Uppsala, Sweden).

Enzymatic activity of PSA forms was monitored by zymogram gel electrophoresis using non-boiled sample aliquots in 0.75 mm thick, 12 %T, 2.67 %C polyacrylamide gels containing 0.1% gelatin from porcine skin (Sigma, Steinheim, Germany) under non-reducing conditions in the presence of SDS. In order to refold the proteins allowing re-gain their enzymatic activity, the

detergent was removed by washing with Triton X-100 and the gels were incubated overnight at 37°C in Zymogram Development Buffer (Invitrogen, Carlsbad, CA). Staining was performed with Coomassie blue R350 for 1 h according to the manufacturer's recommendations.

The molecular weights of proteins were calculated by comparing their migration distances to the positions of molecular weight standards, using Quantity One software (Bio-Rad, Hercules, CA). Further on, the major form of PSA (ca. 32 kDa), identified in all samples, was used for normalization of molecular weights of proteins in the gels.

2.3. Mass spectrometry

The major protein bands observed within the size region between 20-40 kDa in SDS-PAGE gels were cut and analyzed by MALDI mass spectrometry following in-gel tryptic digestion. All analyses were performed in triplicates. Full mass scans and MS/MS spectra were generated on a MALDI LTQ Orbitrap XL instrument (Thermo Scientific, Bremen, Germany) using two acquisition methods consecutively on each spot. First, the FT mass analyzer (Orbitrap) of the mass spectrometer was utilized for full MS data collection in positive mode within a mass range of 600-4000 Da at 60,000 resolution. Laser energy was set to 10 µJ. Each dry droplet spot was sampled by acquiring 20 FT mass scans in 2 microscan/scan steps, allowing the software to select positions automatically based on the matrix crystals (Crystal Positioning System). The monoisotopic masses were extracted from the averaged spectra by using the built-in Extract script of the Xcalibur software v2.0.7.

The second method for peptide sequence data collection utilized the linear ion trap mass analyzer of the hybrid instrument. The data acquisition was performed on the 25 most intense signals, which exceeded the minimal intensity of 500 counts and matched with the inclusion mass list theoretically created by *in silico* digestion of 35 PSA isoforms using the PeptideMass tool (<http://expasy.org/tools/peptide-mass.html>). For fragmentation the normalized collision energy was set to 50% and the activation Q to 0.250 for an activation time of 30 ms.

In-gel digests of enzymatically active proteins within the size region of 20-40 kDa in zymogram gels were analyzed by nanoLC-MS/MS. An HTC-PAL autosampler (CTC Analytics AG) was employed for 2 μ L injection of samples, which were first trapped on a 4.5 cm long C₁₈-precolumn (100 μ m i.d.). Then reversed-phase separation of peptides was performed on a 20 cm long fused silica column (50 μ m i.d.) packed with ReproSil-Pur C₁₈-AQ 3 μ m porous particles (Dr. Maisch GmbH, Germany). The linear gradient started after 6 min of isocratic run at 5% ACN/0.2% formic acid and reached 50% ACN in 34 min at 200 nL/min flow rate using a binary pump (Agilent 1100) with splitter. The LTQ FT-ICR (Thermo Electron), a hybrid mass spectrometer equipped with linear ion trap, Fourier transform ion cyclotron (7 T magnet) was operated in data dependent mode switching between MS and MS/MS acquisitions automatically. While the FT-ICR mass analyzer acquired survey MS spectra in the range of 400-2000 Da, the linear ion trap was used for fragmentation and detection of the five most abundant ions selected from each FT-MS scan. The inclusion mass list of PSA peptides was used for parent ion selection but other precursors were also fragmented when no masses from the inclusion list were present. Additionally,

an exclusion list of masses originating from the background proteins (mostly gelatin) in zymogram gels was applied. The exclusion time for isobaric precursor ions was 20 s and at least 1000 counts were required for fragmentation. The normalized collision energy was set to 50% and the activation Q to 0.250 for an activation time of 30 ms.

2.4. Data analysis

Protein identification based on high resolution MALDI-MS data was performed by peptide mass fingerprinting (PMF) using extracted mass lists on the Mascot search engine (<http://www.matrixscience.com>) with the NCBI database (release 20091024, 224,815 out of 9,937,670 sequences), which contained the highest number of PSA isoforms. The parameters of fixed carbamidomethylation and variable oxidation modifications at cysteine and methionine residues were used respectively. The peptide tolerance of 10 ppm was used throughout database search. Positive PSA annotations by PMF were considered only when at least two specific peptides were identified in at least two of the technical triplicates.

The Proteios Software Environment (ProSE) [34] was employed for combining multiple search results using MALDI-MS/MS sequencing data, which is provided by the built-in interfaces of ProSE to protein identification engines [35]. We have simultaneously used both Mascot and X!Tandem with native k-score scoring, searching the IPI Human database [36] version 3.71 (containing 86,745 protein sequences). The precursor mass tolerance was set to 10 ppm, whereas the fragment tolerance was 0.5 Da. The cysteine and methionine residues were modified with fixed carbamidomethylation and variable oxidation, respectively.

The filtering criterion of protein identification was defined as at least two PSA peptides required with an FDR less than 0.01 [35].

The enzymatically active PSA forms were identified by the tandem mass spectra generated on FT-ICR, using Proteome Discoverer version 1.1 (Thermo Fisher Scientific) applying Mascot search engine on the SwissProt database (March 2010). The database interrogation parameters were set to include the same mass tolerance windows and amino acid modifications as above but two missed cleavages were allowed.

3. Results and Discussion

We have analyzed seminal plasma samples from young men seeking medical aid due to infertility (n=29) and compared those to healthy controls (n=5). Seminal plasma was chosen in this study because of the fact that the major portion of PSA molecules is in free forms, which enhances the identification of possible PSA isoforms in this proximal fluid. Electrophoretic decomplexing and mass spectrometry based protein identification was employed according to our method reported previously [31]. As **Figure 1** illustrates, the PSA expression profiles of clinical samples were determined by MALDI-MS generating accurate masses and peptide sequences, as well as the monitoring by Western blot analysis. Additionally, in this study we have extended the use of high resolving MS (FT-ICR), resulting in unambiguous protein annotations in zymogram gel bands, which has enabled us to identify enzymatically active PSA isoforms even in the presence of a high chemical background.

Both the free PSA (fPSA) and total protein concentrations of seminal samples were determined by commercial DELFIA and Bradford methods, respectively. The fPSA values were in the range of 0.233-1.915 mg/mL, whereas the total protein concentration varied between 7.715 and 22.097 mg/mL (see Table 1). The 34 individual samples revealed weak correlation between the level of total protein and PSA expression (correlation coefficient=0.62). With the study n-number, we were not able to show statistically significant differences in-between total protein- and fPSA-expressions within the two study groups, as shown in **Figure 2A**. The mean fPSA expression (relative to the total protein levels) was found to be 5% (**Figure 2B**), whereas the median value was 4.4% (minimum=2.0% and maximum=10.4%). Interestingly, four samples clearly deviated from average in the region of high fPSA expression (above 8%), including one healthy control sample. The other four control samples scattered around the median value.

3.1. Evaluation of PSA forms in clinical samples

Following calculation of the molecular weights (Mw) of protein bands relative to the molecular standards, these values were corrected within each gel on a band of unknown protein at about 44 kDa present in all samples. Further corrections were made in between gels, modifying the calculated Mw values by the difference of the reference band of the unknown protein band relative to 44.07 kDa (variation was less than 2.52 kDa). Since a major form of PSA (31.6 kDa) was clearly identified in all samples, this band was used for final normalization of all PSA bands. Protein bands in the higher size range (30 kDa and above) agreed excellently in all gels, but those bands at lower positions (below 25 kDa)

scattered more in their calculated Mw values due to the more pronounced diffusion. Therefore, their optical detection was more difficult, which contributed to a less reliable determination of their molecular weights.

3.2. PSA expression in seminal fluid

In gel bands under reducing conditions, we could unambiguously identify single or double PSA forms at very close positions in 53% of the samples, combining accurate mass (FT full MS) and sequence (MS/MS) based database search, marked by asterisks in **Figure 3** (samples SP5, SP6, SP8-16, SP20, SP23, SP24, SP26-28, SPC3 and SPC5). In these cases, a comparison with a single PSA form, detected by monoclonal antibody 2E9 in Western analysis, agreed well with PSA form at 31.6 kDa. A detailed list of PSA identifications by both peptide mass fingerprint and sequences is provided in the Supplementary Table.

In the remaining of the samples (47%), more than 2 PSA forms could be identified by MS, where 3-9 molecular variants were observed (**Figure 3**). Although, in 2 of these cases Western analysis also indicated multiple PSA forms, the mAb 2E9 missed the clear-cut detection of a significant portion of PSA in the remaining 12 seminal plasma samples.

Since the sample volume applied on gels was normalized to the total protein amount (88 µg), the amount of fPSA varied in the range of 1.78-9.13 µg. We have observed that the higher the fPSA amount in gel the more molecular forms could be identified by MS. In 16 samples more than 2 forms were detected and the relative fPSA expression was above the median value (4.37%) in 12 out of 16, corresponding to 75% of these samples. In those samples, where more than 3 molecular forms of PSA were identified by MS (10 samples in total), 7 samples

were within the highest 10 relative fPSA expression levels. On the other hand, in 12 out of 18 cases, where single or double forms of PSA were detected, the relative fPSA expression was below the median value. Interestingly, single PSA forms were detected in two samples (SP13 and SP15) with high relative PSA expression levels. Consequentially, as the strong correlation between the number of observed molecular forms and the amount of PSA applied in gels indicated, more variants could be present in all samples, but the concentration being below the limit of detection.

3.3. Enzymatically active PSA forms

The zymogram separation pattern generated 3-6 enzymatically active protein bands that migrated to the same positions within a 20-40 kDa, range in each gel. An apparent similarity of the respective PSA band distribution was evident, although the calculated Mw-values were not identical with those determined in SDS-PAGE gels due to the different gel compositions. By comparing protein expression patterns, the corresponding protein band distribution (separated under SDS-PAGE and zymogram gel conditions), with major PSA forms at 31.6 and 35.0 kDa, were found to be identical. We also identified active double bands, in our zymogram images, at low Mw-positions (see bands at 23.9 and 25.4 kDa in **Figure 4**) that we identified as being highly similar to the 23-27 kDa region (SDS-PAGE), where only a single band appeared with a broad and diffused elution profile.

In an attempt to associate the observed enzymatic activity in the zymogram gels with PSA specificity, the unstained bands were subjected to PSA sequencing using the FT-ICR high accuracy mass spectrometer. The FT-ICR platform allowed

us to identify PSA forms in the presence of high chemical background. As exemplified with two of the patient samples; SP21 and SP22, we were able to observe 6 enzymatically active bands. Out of these forms, the highest Mw position was detected as 35 kDa, and positively identified as the major form of PSA by FT-ICR with patient SP22 only. The weak activity band in patients SP21 did not allow a positive sequence identity of PSA. Interestingly, patient SP21 showed positive identity by both sequencing, and activity for additionally four PSA forms (29.5, 28.1, 25.4 and 23.9 kDa), whereas the 28.1 kDa PSA form was found to be expressed by patient SP22 as well. The strategy outlined above, allowed us to predict the combined effects of enzyme activity in patient samples with a target identity of PSA.

3.4. Correlation analysis

Due to the high resolving power of modern proteomic platforms, we were able to detect the highest number of PSA forms and sequence information that has been identified, as of today, describing a multitude of molecular forms of PSA in seminal fluid. We captured the clinical data of the participants in the study, where age, semen volume, and zinc, fructose and albumin levels were determined. These study data formed the basis for the statistical analysis. The study members were shown to group well in the isomap plot, which lays out the samples in space, revealing the network clustering (see **Figure 5A**). **Figure 5B** shows these separated sample groups as a heat map, where samples with high albumin levels (calculated to be above the third quartile of the data set) gathered in the Red group and to a less extent in the Green group. In addition, the majority of the samples with low fructose and zinc concentrations (which came clear

below the first quartile of the data set) were found in the Orange group and to a less extent in the Red group (see **Figure 5B**). Interestingly, we found that the samples with low semen volumes in the Red group also have (found below the first quartile of the data set), yet only one patient in this group is identified above the third quartile of age. All of these hierarchical clustering analyses were performed using the Qlucore Omics Explorer v2.1. software.

In the second step of the statistical evaluation, we investigated the Red and Orange groups that proved to have the highest risk for male factor infertility and followed their positioning when the proteomic data were combined with clinical information. Accordingly, besides the clinical data, the levels of fPSA and total protein concentrations, the number of peptides, and the sequences by both MS and Western analysis were included as variables for a multi group comparison. The following variables remained in this hierarchical clustering analysis after filtering by variance ($\sigma/\sigma_{\max}=0.27$): total protein and fructose concentrations, semen volume, age and three identifications of PSA. The resulting isomap and heat map representations revealed a formation of four groups that are displayed in **Figure 5C and D**. Remarkably, the patients with high albumin levels (Red group in Figure 5A and B) grouped well together in the Yellow group (see **Figure 5C and D**). These findings are in good correlation with the first analysis round, where the separation of these patients was found to sustain with a strong correlation to an ongoing inflammation. The group of patients with low fructose and zinc levels (Orange group in **Figure 5A and B**) was also clearly separated in the Green group (**Figure 5C and D**).

Interestingly, the samples in the Blue group typically had low semen volumes but without any correlations to additional risk factors. The control samples were

grouped in the Red and Blue groups, with a clear separation from the patients with male factor infertility (in the Green and Yellow groups within **Figure 5C**).

The peptide sequences as variables from both PMF and MS/MS identification with the major expressed PSA form (at 31.6 kDa) indicated that the number of identified tryptic peptides was one of the most important separating factors in this analysis. Further, detailed investigation of the identified PSA peptide sequences in these separated groups (Yellow and Green in **Figure 5C and D**) revealed the highest number of peptide annotations.

4. Conclusions

In our opinion it becomes increasingly evident that PSA as a single marker needs additional and higher resolution data for improved disease speciation and predictive outcome. Despite notable advances in our understanding of the molecular and functional details of PSA, there is still lacking consensus as to which may be the best strategy to obtain optimal clinical value from PSA-testing [19]. Consequently, our observation of various isoforms of PSA in patients reported in this communication can contribute to important insight in identification of disease-relevant heterogeneity of PSA, including transcriptional and post-translational modifications present due to various stages and causes of prostate disease. In order to get an in-depth understanding of the metabolism of PSA and its variety of modified forms in blood and semen we need to extend the investigation on clinically relevant material to gather sufficient statistical data and elucidate the clinical potential of profiling PSA isoforms.

5. Non-standard Abbreviations

PSA, prostate specific antigen; PCa, prostate cancer, BHP, benign prostatic hyperplasia; tPSA, total PSA; fPSA, free PSA

6. Acknowledgments

We would like to thank Gun-Britt Eriksson at the Dept. of Clinical Chemistry, University Hospital in Malmö, Sweden, for technical assistance; Martin Hornshaw and Egon Rosén at Thermo Fisher Scientific, for mass spectrometry support. The authors are grateful for funding support from the Swedish Research Council, Vinnova and Foundation for Strategic Research – The Programme: Biomedical Engineering for Better Health – grant no: 2006-7600 and grant no: K2009-54X-20095-04-3 and grant no. 2009-5361, Swedish Cancer Society (08-0345), Knut and Alice Wallenberg Foundation, Crafoord Foundation, Carl Trygger Foundation, Fundación Federico SA, Royal Physiographic Society, Sten Lexner Foundation, Sidney Kimmel Center for Prostate and Urologic Cancers, National Cancer Institute Specialized Programs of Research Excellence (P50-CA92629) and David H. Koch through the Prostate Cancer Foundation.

7. Conflict of interest

Dr. Hans Lilja holds patents for free PSA and kallikrein-2 (hK2) assays. All other authors declare no conflict of interest.

8. References

- [1] H. Lilja, D. Ulmert, T. Bjork, C. Becker, A.M. Serio, J.A. Nilsson, et al., Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. *J. Clin. Oncol.* 25 (2007) 431-436.
- [2] I.M. Thompson, D.K. Pauler, P.J. Goodman, C.M. Tangen, M.S. Lucia, H.L. Parnes, et al., Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4.0 ng per milliliter. *N. Engl. J. Med.* 350 (2004) 2239-2246.
- [3] F.H. Schröder, J. Hugosson, M.J. Roobol, T.L.J. Tammela, S. Ciatto, V. Nelen, et al., Screening and Prostate-Cancer Mortality in a Randomized European Study. *N. Engl. J. Med.* 360 (2009) 1320-1328.
- [4] Å. Lundwall, and H. Lilja, Molecular cloning of human prostate specific antigen cDNA. *FEBS Letters* 214 (1987) 317-322.
- [5] H.G. Rittenhouse, J.A. Finlay, S.D. Mikolajczyk, and A.W. Partin, Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. *Crit. Rev. Clin. Lab. Sci.* 35 (1998) 275-368.
- [6] E.I. Canto, H. Singh, S.F. Shariat, D.J. Lamb, S.D. Mikolajczyk, H.J. Linton, et al., Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. *Urology* 63 (2004) 905-910.
- [7] S.D. Mikolajczyk, L.S. Millar, T.J. Wang, H.G. Rittenhouse, R.L. Wolfert, L.S. Marks, et al., "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. *Urology* 55 (2000) 41-45.

- [8] M.F. Darson, A. Pacelli, P. Roche, H.G. Rittenhouse, R.L. Wolfert, M.S. Saeid, et al., Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. *Urology* 53 (1999) 939-944.
- [9] K.W.K. Watt, P.-J. Lee, T. M'Timkulu, W.-P. Chan, and R. Loor, Human Prostate-Specific Antigen: Structural and Functional Similarity with Serine Proteases. *Proc. Natl. Acad. Sci. USA* 83 (1986) 3166-3170.
- [10] J. Lövgren, K. Rajakoski, M. Karp, Å. Lundwall, and H. Lilja, Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. *Biochem. Biophys. Res. Comm.* 238 (1997) 549-555.
- [11] T.K. Takayama, K. Fujikawa, and E.W. Davie, Characterization of the Precursor of Prostate-specific Antigen *J. Biol. Chem.* 272 (1997) 21582-21588.
- [12] N. Emami, and E.P. Diamandis, Human Kallikrein-related Peptidase 14 (KLK14) Is a New Activator Component of the KLK Proteolytic Cascade. *J. Biol. Chem.* 283 (2008) 3031-3041.
- [13] H. Lilja, A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. *J. Clin. Invest.* 76 (1985) 1899-1903.
- [14] H. Lilja, J. Oldbring, G. Rannevik, and C.B. Laurell, Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. *J. Clin. Invest.* 80 (1987) 281-285.
- [15] E. Pezzato, L. Sartor, I. Dell Aica, R. Dittadi, M. Gion, C. Belluco, et al., Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (-)epigallocatechin-3-gallate. *Int. J. Cancer* 112 (2004) 787-792.

- [16] A. Christensson, and H. Lilja, Complex-Formation between Protein-C Inhibitor and Prostate-Specific Antigen In-Vitro and in Human Semen. *Eur. J. Biochem.* 220 (1994) 45-53.
- [17] F. Espana, J. Gilabert, A. Estelles, A. Romeu, J. Aznar, and A. Cabo, Functionally Active Protein-C Inhibitor Plasminogen-Activator Inhibitor-3 (PCI/PAI-3) Is Secreted in Seminal-Vesicles, Occurs at High-Concentrations in Human Seminal Plasma and Complexes with Prostate-Specific Antigen. *Thromb. Res.* 64 (1991) 309-320.
- [18] M. Laurell, A. Christensson, P.A. Abrahamsson, J. Stenflo, and H. Lilja, Protein-C Inhibitor in Human-Body Fluids - Seminal Plasma Is Rich in Inhibitor Antigen Deriving from Cells Throughout the Male Reproductive-System. *J. Clin. Invest.* 89 (1992) 1094-1101.
- [19] H. Lilja, D. Ulmert, and A.J. Vickers, Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. *Nat. Rev. Cancer* 8 (2008) 268-278.
- [20] T.J. Walsh, M. Schembri, P.J. Turek, J.M. Chan, P.R. Carroll, J.F. Smith, et al., Increased Risk of High-Grade Prostate Cancer Among Infertile Men. *Cancer* 116 (2010) 2140-2147.
- [21] D.A. Armbruster, Prostate-specific antigen: biochemistry, analytical methods, and clinical application. *Clin. Chem.* 39 (1993) 181-195.
- [22] A. Bélanger, H. van Halbeek, H.C.B. Graves, K. Grandbois, T.A. Stamey, L. Huang, et al., Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. *Prostate* 27 (1995) 187-197.

- [23] W.-M. Zhang, J. Leinonen, N. Kalkkinen, B. Dowell, and U.-H. Stenman, Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. *Clin. Chem.* 41 (1995) 1567-1573.
- [24] G. Tabares, C.M. Radcliffe, S. Barrabes, M. Ramirez, R.N. Aleixandre, W. Hoesel, et al., Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA. *Glycobiology* 16 (2006) 132-145.
- [25] H. Hiltz, J. Noldus, P. Hammerer, F. Buck, M. Lück, and H. Huland, Molecular heterogeneity of free PSA in sera of patients with benign and malignant prostate tumors. *Eur. Urol.* 36 (1999) 286-292.
- [26] T. Isono, T. Tanaka, S. Kageyama, and T. Yoshiki, Structural Diversity of Cancer-related and Non-Cancer-related Prostate-specific Antigen. *Clin. Chem.* 48 (2002) 2187-2194.
- [27] T. Okada, Y. Sato, N. Kobayashi, K. Sumida, S. Satomura, S. Matsuura, et al., Structural characteristics of the N-glycans of two isoforms of prostate-specific antigens purified from human seminal fluid. *Biochim. Biophys. Acta* 1525 (2001) 149-160.
- [28] S. Prakash, and P.W. Robbins, Glycotyping of prostate specific antigen. *Glycobiology* 10 (2000) 173-176.
- [29] S.D. Mikolajczyk, L.S. Grauer, L.S. Millar, T.M. Hill, A. Kumar, H.G. Rittenhouse, et al., A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. *Urology* 50 (1997) 710-714.
- [30] J. Noldus, Z. Chen, and T.A. Stamey, Isolation and characterization of free form prostate specific antigen (f-PSA) in sera of men with prostate cancer. *J. Urol.* 158 (1997) 1606-1609.

- [31] Á. Végvári, M. Rezeli, C. Welinder, J. Malm, H. Lilja, G. Marko-Varga, et al., Identification of Prostate Specific Antigen (PSA) Isoforms in Complex Biological Samples Utilizing Complementary Platforms. *J. Proteomics* 73 (2010) 1137-1147.
- [32] E.F. Dickson, A. Pollak, and E.P. Diamandis, Ultrasensitive Bioanalytical Assays Using Time-Resolved Fluorescence Detection. *Pharmacol. Therapeut.* 66 (1995) 207-235.
- [33] K. Pettersson, T. Piironen, M. Seppala, L. Liukkonen, A. Christensson, M.T. Matikainen, et al., Free and Complexed Prostate-Specific Antigen (PSA) - In-Vitro Stability, Epitope Map, and Development of Immunofluorimetric Assays for Specific and Sensitive Detection of Free PSA and PSA-Alpha(1)-Antichymotrypsin Complex. *Clin. Chem.* 41 (1995) 1480-1488.
- [34] J. Häkkinen, G. Vincic, O. Månsson, K. Wårell, and F. Levander, The Proteios Software Environment: An Extensible Multiuser Platform for Management and Analysis of Proteomics Data. *J. Proteome Res.* 8 (2009) 3037-3043.
- [35] F. Levander, M. Krogh, K. Wårell, P. Gärdén, P. James, and J. Häkkinen, Automated reporting from gel-based proteomics experiments using the open source Proteios database application. *Proteomics* 7 (2007) 668-674.
- [36] P.J. Kersey, J. Duarte, A. Williams, Y. Karavidopoulou, E. Birney, and R. Apweiler, The International Protein Index: An integrated database for proteomics experiments. *Proteomics* 4 (2004) 1985-1988.

Legends to the Figures

Figure 1. Illustration of the mass spectrometry-based proteomics strategy developed for identification of PSA forms in seminal fluid samples.

Figure 2. (A) Distribution plot of seminal fluid for total protein vs. free PSA concentrations. Based on these quantitative values the patient and control groups cannot be separated. (B) The distribution of relative PSA expressions (to the total protein amount) depicted as box plot diagram. The average value was 4.9%, whereas the RSD was 41%.

Figure 3. Summarized data of molecular forms of PSA identified by both peptide fingerprint and sequences. The dark boxes indicate molecular forms of PSA as identified by both peptide mass fingerprinting and sequences from high resolution MALDI Orbitrap data.

Figure 4. Illustration of enzymatically active PSA forms in zymograms demonstrated with two examples as identified by high resolution FT-ICR mass spectrometry.

Figure 5. Isomap and heat map representation of the classical hierarchical clustering applied on the data set generated with (A and B) 5 clinically relevant parameters separately and (C and D) in combination with proteomic data of 34 individual seminal fluid samples. Samples associated with risk factors of male infertility were identified in the Red and Orange groups (A and B), which were re-grouped in Green and Yellow upon combination with proteomic data (C and D).

List of Supplementary Material

Table S1. Summarized data of peptide fingerprint (PMF), sequencing (MS/MS), zymogram and Western identification of PSA forms.




Figure 1




Figure 2.




Figure 3.




Figure 4.





Figure 5.

Table 1. Summarized data of seminal plasma samples used in this study. Patient samples are numbered 1-29, whereas healthy control samples are denoted as C1-C5.

Sample ID	Age (year)	Semen volume (mL)	Protein (mg/mL)	Albumin (mg/mL)	Fructos (mM)	Zinc (mM)	fPSA (mg/mL)	Nr of PSA form in SDS-PAGE (PMF/Sequence)	Nr of PSA form in Zymogram	Nr. of PSA form in Western
1	28	4.1	10.879	1	12.1	1.6	0.580	4 / 6	2	1
2	39	2.8	12.142	0.6	10.2	2.2	0.725	4 / 3	n.a.	1
3	46	4.6	16.053	0.5	13.8	2.8	0.655	2 / 3	n.a.	1
4	34	2.5	14.311	0.9	9	1.4	0.590	3 / 2	1	1
5	35	6.5	19.697	1	27	2.9	0.425	1 / 1	n.a.	1
6	36	5	11.395	0.5	18.7	1.3	0.459	1 / 1	n.a.	1
7	36	5	13.013	0.5	20.1	1.6	0.505	3 / 2	4	1
8	42	5.2	11.626	0.8	6.6	0.9	0.462	1 / 1	2	1
9	38	5.1	10.755	0.5	14.4	0.8	0.324	2 / 2	n.a.	1
10	40	3.8	16.853	0.8	14.9	1.8	0.493	2 / 1	1	1
11	41	6	7.893	0.4	13	0.7	0.344	2 / 1	n.a.	1
12	38	6.3	12.639	0.4	9.5	1.1	0.414	1 / 1	n.a.	1
13	35	5.9	10.648	0.4	8.4	1.2	0.695	1 / 1	n.a.	1
14	39	2.2	21.511	1.5	7.4	3	1.035	2 / 2	n.a.	1
15	42	3.1	13.493	0.7	16	2.8	0.930	2 / 1	3	1
16	36	3.1	15.146	1.3	11	2.4	0.610	2 / 1	n.a.	1
17	30	2.2	13.688	0.7	6.3	1.8	0.815	3 / 1	n.a.	2
18	32	5.7	12.444	0.5	14.5	0.8	0.368	2 / 2	n.a.	1
19	34	2.5	21.511	1.1	2	4.2	1.915	4 / 6	n.a.	1
20	37	7.8	12.195	0.7	23.3	1.8	0.590	2 / 2	n.a.	1
21	33	7.1	7.715	0.2	6.5	1.6	0.800	7 / 8	4	1
22	37	4	19.537	0.8	14.3	3.6	1.265	3 / 5	2	1
23	36	7.8	11.519	0.5	11.8	0.9	0.233	2 / 2	n.a.	1
24	31	4	9.315	0.3	18	0.9	0.409	1 / 1	n.a.	1

25	37	4.2	16.568	0.5	11.9	3.4	1.140	4 / 1	n.a.	1
26	41	4.3	18.364	0.6	9.5	2.9	0.755	1 / 1	1	1
27	37	3.2	8.568	0.6	14.1	1.9	0.310	2 / 1	2	3
28	42	3	20.142	0.4	15.6	1.9	0.499	1 / 1	n.a.	1
29	36	4.2	13.831	0.8	8.1	4	1.320	3 / 5	1	1
C1	n.a.	n.a.	11.982	n.a.	n.a.	n.a.	0.630	3 / 2	1	3
C2	n.a.	n.a.	22.098	n.a.	n.a.	n.a.	1.855	3 / 6	3	1
C3	n.a.	n.a.	16.320	n.a.	n.a.	n.a.	0.690	2 / 2	0	1
C4	n.a.	n.a.	19.360	n.a.	n.a.	n.a.	0.900	4 / 4	n.a.	1
C5	n.a.	n.a.	16.035	n.a.	n.a.	n.a.	0.760	2 / 2	n.a.	3

Supplementary Table 1.

The major molecular form of PSA at 31.6 kDa is indicated in bold italics type setting. The peptide sequences in the table are arranged to match the corresponding m/z values where applicable. Also, the PSA peptides are listed in sequential order from the N-terminus. Oxidation of methionine ($\Delta\text{mass}=15.9949$) is highlighted with asterisk (M*) and sequences with and without oxidized methionine are listed separately. All cysteine residues were carbamidomethylated ($\Delta\text{mass}=57.034$) and thus not indicated separately. Peptide masses (as identified by PMF) corresponding to peptides with one missed cleavage are underlined. In several cases, the sequence, AVCGGVLVHPQWVLTAHCIR ($m/z=2344.2178$) was identified in a truncated form (AVCGGVLVHPQWVLTAAH) by the X!Tandem database.

Sample ID	Mw (kDa)	PMF identification	Sequence identification	Enzymatic activity	Western identification		
1	34.6	1077.5035		-	-		
		1407.7506	HSQPWQVLVASR				
		757.4916					
		1887.9411	FLRPGDDSSHDLM*LLR				
		1272.6703					
		2588.3088	KLQCVDLHVISNDVCAQVHPQK				
		2460.2161	LQCVDLHVISNDVCAQVHPQK				
		854.4006					
		870.3955					
		673.3769					
		33.1	1077.5028	IVGGWECEK		-	-
			1407.7506	HSQPWQVLVASR			
			757.4916				
				FLRPGDDSSHDLM*LLR			
	1887.9398		FLRPGDDSSHDLM*LLR				
	1272.6687		LSEPAELTDAVK				
	2588.3079		KLQCVDLHVISNDVCAQVHPQK				
	2460.2129		LQCVDLHVISNDVCAQVHPQK				
	854.3999						
	870.3947						
	31.6	673.3762	VVHYR				
		1077.5037	IVGGWECEK		-	+	
		1407.7517	HSQPWQVLVASR				
		757.4926					
			FLRPGDDSSHDLM*LLR				
		1887.9416	FLRPGDDSSHDLM*LLR				
		1272.6695	LSEPAELTDAVK				
2588.3101		KLQCVDLHVISNDVCAQVHPQK					
2460.2156		LQCVDLHVISNDVCAQVHPQK					
854.4009		FMLCARG					
30.5	870.3958						
	673.3769	VVHYR					
	1077.503	IVGGWECEK		+	-		
	1407.7505	HSQPWQVLVASR					
	757.4922						
	1887.9406						
	1272.6688	FLRPGDDSSHDLM*LLR					
	2588.3075	KLQCVDLHVISNDVCAQVHPQK					
	2460.2136	LQCVDLHVISNDVCAQVHPQK					
	854.4004						
	870.3953						
	673.3766	VVHYR					
	25.9			+	-		
23.0		FLRPGDDSSHDLM*LLR	-	-			
21.8		FLRPGDDSSHDLM*LLR	-	-			
2	31.6	1077.5039	IVGGWECEK	<i>n.a.</i>	+		
		1407.7522	HSQPWQVLVASR				

		2344.2241			
		757.4927	SVILLGR		
		1871.9474	FLRPGDDSSHDLMLLR		
		1887.9428	FLRPGDDSSHDLM*LLR		
		1272.6698	LSEPAELTDAVK		
		2588.3029	KLQCVDLHVISNDVCAQVHPQK		
		2460.2045	LQCVDLHVISNDVCAQVHPQK		
		854.4012	FMLCARG		
		870.3959			
		673.3771	VVHYR		
30.5		1077.5027	IVGGWECEK	n.a.	-
		1407.7498			
		757.4917			
		1871.9447			
		1272.6681			
		854.4001			
		870.3952			
		673.3764			
23.0		1077.5038	IVGGWECEK	n.a.	-
		1407.7513	HSQPWQVLVASR		
		757.4926			
		1871.9465			
		1272.6697			
		854.4004			
21.8		1077.5027		n.a.	-
		1407.7497			
		757.4919			
		1272.668			
3	31.6	1077.5027	IVGGWECEK	n.a.	+
		1407.7504	HSQPWQVLVASR		
		757.4919	SVILLGR		
		1871.945	FLRPGDDSSHDLMLLR		
		1887.9412	FLRPGDDSSHDLM*LLR		
			LSEPAELTDAVK		
		2588.3089	KLQCVDLHVISNDVCAQVHPQK		
			LQCVDLHVISNDVCAQVHPQK		
		854.4003			
		870.3953			
		673.3765			
	30.5		FLRPGDDSSHDLMLLR	n.a.	-
			LSEPAELTDAVK		
	23.0	1077.5036	IVGGWECEK	n.a.	-
		1407.7511			
		757.4924			
		1871.9472	FLRPGDDSSHDLMLLR		
		1272.6696	LSEPAELTDAVK		
4	40.0	1077.503	LSEPAELTDAVK	-	-
		1407.7506			
		757.4922			

		1887.9402			
		1272.6691			
	31.6	1077.5044	IVGGWECEK	-	+
		1407.7528	HSQPWQVLVASR		
		2344.2222	AVCGGVLVHPQWVLTAAH(CIR)		
		757.4929	SVILLGR		
		3509.6876			
		1871.9484	FLRPGDDSSHDLMLLR		
		1887.9432	FLRPGDDSSHDLM*LLR		
		1272.6703	LSEPAELTDAVK		
		2588.3119	KLQCVDLHVISNDVCAQVHPQK		
		2460.218	LQCVDLHVISNDVCAQVHPQK		
		854.4014			
		870.396			
			VVHYR		
	25.9	1077.5028		-	-
		1407.7496			
		757.4919			
		1887.9391			
		1272.6679			
	23.0			+	-
5	31.6	1077.5039	IVGGWECEK	n.a.	+
		1407.7521	HSQPWQVLVASR		
		757.4923			
		1871.9461	FLRPGDDSSHDLMLLR		
		1272.6698			
		854.4015	FMLCAGR		
		870.3963			
		673.3776			
6	31.6	1077.5036	IVGGWECEK	n.a.	+
		1407.7514	HSQPWQVLVASR		
		757.4924			
		1871.9465	FLRPGDDSSHDLMLLR		
		1887.9422			
		1272.6694	LSEPAELTDAVK		
		854.4009	FMLCAGR		
		870.3956			
		673.3771			
7	34.6	1077.503		-	-
		1407.7512			
		757.4919			
		1871.9443			
		1272.6692	LSEPAELTDAVK		
		854.4009			
		870.3961			
		673.377			
	33.1	1077.5037		-	-
		1407.751			
		757.4925			

		1871.946			
		1887.9445			
		1272.6693			
		854.4008			
		870.3954			
		673.3769			
	31.6	1077.5034	IVGGWECEK	+	+
		1407.7512	HSQPWQVLVASR		
		757.4923			
		1871.9465	FLRPGDDSSHDLMLLR		
		1887.9427			
		1272.6694	LSEPAELTDAVK		
		854.4007			
		870.396			
	30.5			+	-
	27.0			+	-
	25.9			+	-
8	31.6	1077.5024	IVGGWECEK	+	+
		1407.7495	HSQPWQVLVASR		
		757.4915			
		1871.9438	FLRPGDDSSHDLMLLR		
		1272.6677	LSEPAELTDAVK		
		2588.3063			
		2460.2108			
		854.3999	FMLCAGR		
		870.3946			
	23.0			+	-
9	31.6	1077.5028	IVGGWECEK	n.a.	+
		1407.7504	HSQPWQVLVASR		
		757.492			
		1887.9401	FLRPGDDSSHDLM*LLR		
		1272.6687			
		2588.3087			
		854.4001			
		870.395			
		673.3766	VVHYR		
	30.5	1077.5032	IVGGWECEK	n.a.	-
		1407.751			
		757.4923			
		1887.9401	FLRPGDDSSHDLM*LLR		
		1272.669	LSEPAELTDAVK		
		854.4008			
		870.3955			
		<u>1383.6694</u>			
		673.3769			
10	31.6	1077.5028	IVGGWECEK	-	+
		1407.7499	HSQPWQVLVASR		
			FLRPGDDSSHDLMLLR		
		1272.6681			

		854.4001		
		870.3948		
		673.3765		
30.5		1077.5029	-	-
		1407.7498		
		1272.6683		
		854.3996		
		673.3763		
	23.0		+	-
11	31.6	1077.503	n.a.	+
		1407.7504 HSQPWQVLVASR		
		757.4922		
		1887.94 FLRPGDDSSHDLM*LLR		
		1272.6687		
		854.4004		
		870.3954		
		673.3768 VVHYR		
30.5		1272.6686	n.a.	-
		870.3949		
		673.3764		
12	31.6	1077.504 IVGGWECEK	n.a.	+
		1407.7519 HSQPWQVLVASR		
		757.4929		
		1871.9475 FLRPGDDSSHDLMLLR		
		1887.9426		
		1272.6698 LSEPAELTDAVK		
		854.4012		
		870.3962		
		673.3772		
13	31.6	1407.748	n.a.	+
		757.4913		
		FLRPGDDSSHDLMLLR		
		1887.9388		
		1272.667		
		673.376		
14	31.6	1077.5027 IVGGWECEK	n.a.	+
		1407.7508 HSQPWQVLVASR		
		757.4917 SVILLGR		
		1871.9455 FLRPGDDSSHDLMLLR		
		1887.9419 FLRPGDDSSHDLM*LLR		
		1272.6683 LSEPAELTDAVK		
		2588.3105 KLQCVDLHVISNDVCAQVHPQK		
		2460.2115 LQCVDLHVISNDVCAQVHPQK		
		854.4003 FMLCARG		
		870.3949		
		673.3765		
30.5		1077.5018 IVGGWECEK	n.a.	-
		1407.749		
		1272.6671		

		854.3996			
		870.3947			
		673.3764			
15	31.6	1077.503	IVGGWECEK	+	+
		1407.7506	HSQPWQVLVASR		
		757.492			
		1871.9448	FLRPGDDSSHDLMLLR		
		1887.9444			
		1272.669	LSEPAELTDAVK		
		854.4004	FMLCARG		
		870.3951			
			VVHYR		
	30.5	1077.5023		+	-
		1407.7489			
		757.4914			
		1887.9383			
		1272.667			
		854.3995			
		870.3942			
		673.376			
	23.0			+	-
16	31.6	1077.5019	IVGGWECEK	n.a.	+
		1407.7488	HSQPWQVLVASR		
		757.4912			
		1871.9435	FLRPGDDSSHDLMLLR		
		1272.6672	LSEPAELTDAVK		
		854.3994	FMLCARG		
		870.3946			
		673.3758			
	30.5	1077.5021		n.a.	-
		1272.6681			
		854.3997			
		673.3761			
17	31.6	1077.5029	IVGGWECEK	n.a.	+
		1407.7508	HSQPWQVLVASR		
		757.4919			
		1871.9454	FLRPGDDSSHDLMLLR		
		1887.9414	FLRPGDDSSHDLM*LLR		
		1272.6683	LSEPAELTDAVK		
		2588.3089	KLQCVDLHVISNDVCAQVHPQK		
		2460.211	LQCVDLHVISNDVCAQVHPQK		
		854.4003	FMLCARG		
		870.395			
		673.3766	VVHYR		
	30.5	1077.5028		n.a.	-
		1407.7504			
		757.4917			
		1871.9465			
		1272.6684			

		854.4001			
		870.3943			
		673.3762			
23.0		1077.5012		n.a.	-
		1407.7481			
		757.4913			
		1871.9415			
		1272.6667			
		854.3985			
18	31.6	1077.5024	IVGGWECEK	n.a.	+
		1407.7489	HSQPWQVLVASR		
		757.4915			
		1871.9441	FLRPGDDSSHDLMLLR		
		1887.9403			
		1272.6682	LSEPAELTDAVK		
		854.3995			
		870.3945			
		673.376	VVHYR		
30.5		1077.5012		n.a.	-
		1407.7474			
		757.4909			
		1272.6675			
		854.3988			
		673.3756			
	23.0		LSEPAELTDAVK	n.a.	-
19	31.6	1077.5023	IVGGWECEK	n.a.	+
		1407.7502	HSQPWQVLVASR		
		2344.2178	AVCGGVLVHPQWVLTAAH_CIR		
		757.4916	SVILLGR		
		3509.6896	HSLFHPEDTGQVFQVSHSFPHPPLYDM*SLLK		
			FLRPGDDSSHDLMLLR		
		1887.9403	FLRPGDDSSHDLM*LLR		
		1272.6679	LSEPAELTDAVK		
		2588.3068	KLQCVDLHVISNDVCAQVHPQK		
		2460.213	LQCVDLHVISNDVCAQVHPQK		
		854.4	FMLCARG		
		870.3947			
		673.3763	VVHYR		
30.5		1077.5019	IVGGWECEK	n.a.	-
		1407.7487	HSQPWQVLVASR		
		757.4911			
		1887.9383	FLRPGDDSSHDLM*LLR		
		1272.667			
		2588.3025			
		2460.2104			
		854.399			
		870.3943			
		673.3758	VVHYR		
25.9			IVGGWECEK	n.a.	-

			HSQPWQVLVASR		
			FLRPGDDSSHDLMLLR		
24.4	1077.5024		IVGGWECEK	n.a.	-
	1407.7499		HSQPWQVLVASR		
	757.4917				
	1887.9398		FLRPGDDSSHDLMLLR		
	1272.6681		LSEPAELTDAVK		
23.0	1077.5018		IVGGWECEK	n.a.	-
	1407.7488		HSQPWQVLVASR		
	757.4912				
	1887.9384		FLRPGDDSSHDLMLLR		
	1272.6674		LSEPAELTDAVK		
21.8			FLRPGDDSSHDLMLLR	n.a.	-
20	31.6	1077.5033	IVGGWECEK	n.a.	+
		1407.7511	HSQPWQVLVASR		
		2344.2211	AVCGGVLVHPQWVLTA AH_CIR		
		757.4923			
		3509.6903			
		1871.9471	FLRPGDDSSHDLMLLR		
		1887.9411	FLRPGDDSSHDLMLLR		
		1272.6694			
		2588.3089	KLQCVDLHVISNDVCAQVHPQK		
		2460.2148	LQCVDLHVISNDVCAQVHPQK		
		854.4007	FMLCARG		
		870.3954			
		673.3767			
	30.5	1077.5025		n.a.	-
		1407.7497	HSQPWQVLVASR		
		2344.227			
		757.4916			
		1887.9395	FLRPGDDSSHDLMLLR		
		1272.6679			
		2588.3065	KLQCVDLHVISNDVCAQVHPQK		
		2460.2116	LQCVDLHVISNDVCAQVHPQK		
		854.4001			
		870.3951			
		673.3763			
21	34.6	1077.5023	IVGGWECEK	-	-
		1407.7491	HSQPWQVLVASR		
			AVCGGVLVHPQWVLTA AH		
		757.4915			
			FLRPGDDSSHDLMLLR		
		1887.9388	FLRPGDDSSHDLMLLR		
		1272.668			
			KLQCVDLHVISNDVCAQVHPQK		
			LQCVDLHVISNDVCAQVHPQK		
		854.3997			
		870.3945			
			ALPERPSLY		

	673.3764			
33.1	1077.5023	IVGGWECEK	-	-
	1407.7492	HSQPWQVLVASR		
		AVCGGVLVHPQWVLTAAH		
	757.4913			
		FLRPGDDSSHDLMLLR		
	1887.9387	FLRPGDDSSHDLM*LLR		
	1272.6676	LSEPAELTDAVK		
	2588.3073	KLQCVDLHVISNDVCAQVHPQK		
	2460.2116	LQCVDLHVISNDVCAQVHPQK		
	854.3997			
	870.3946			
	673.376	VVHYR		
31.6	1077.5029	IVGGWECEK	-	+
	1407.7508	HSQPWQVLVASR		
		AVCGGVLVHPQWVLTAAH		
	757.4919	SVILLGR		
		FLRPGDDSSHDLMLLR		
	1887.9393	FLRPGDDSSHDLM*LLR		
		KLQCVDLHVISNDVCAQVHPQK		
	2460.2133	LQCVDLHVISNDVCAQVHPQK		
	854.4001	FMLCARG		
	870.3951			
	673.3764	VVHYR		
30.5	1077.5031	IVGGWECEK	-	-
	1407.7503	HSQPWQVLVASR		
	757.4919			
	1887.94	FLRPGDDSSHDLM*LLR		
	1272.6686			
	2460.2123			
	870.3949			
	673.3764			
27.0		HSQPWQVLVASR	+	-
25.9		HSQPWQVLVASR	+	-
		FLRPGDDSSHDLM*LLR		
24.4	1077.5028	IVGGWECEK	-	-
	1407.7498	HSQPWQVLVASR		
	757.4918			
	1887.9397	FLRPGDDSSHDLM*LLR		
	1272.6685	LSEPAELTDAVK		
23.0	1077.5023	IVGGWECEK	+	-
	1407.7499	HSQPWQVLVASR		
	757.492			
	1887.9404	FLRPGDDSSHDLM*LLR		
	1272.6687	LSEPAELTDAVK		
21.8	1077.5035		+	-
	1407.7502			
	757.4919			
	1887.9397			

		1272.6686				
22	31.6	1077.5033	IVGGWECEK		+	+
		1407.7507	HSQPWQVLVASR			
		757.492	VVHYR			
		1887.9403	FLRPGDDSSHDLM*LLR			
		1272.6693	LSEPAELTDAVK			
		2588.3098	KLQCVDLHVISNDVCAQVHPQK			
		2460.2145	LQCVDLHVISNDVCAQVHPQK			
		854.4	FMLCARG			
		870.3951				
		673.3764				
	31.6	1077.5034	IVGGWECEK		+	-
		1407.7513	HSQPWQVLVASR			
			AVCGGVLVHPQWVLTAAH			
		757.4923	SVILLGR			
		3509.6976				
		1887.9413	FLRPGDDSSHDLM*LLR			
		1272.669	LSEPAELTDAVK			
		2588.3091	KLQCVDLHVISNDVCAQVHPQK			
		2460.2154	LQCVDLHVISNDVCAQVHPQK			
		854.4005				
		870.3956				
			ALPERPSLY			
		673.3768	VVHYR			
30.5		1077.5031	IVGGWECEK		-	-
		1407.7503	HSQPWQVLVASR			
		757.4922				
		1887.94	FLRPGDDSSHDLM*LLR			
		1272.6689	LSEPAELTDAVK			
		870.3953				
		<u>1383.6693</u>				
		673.3768	VVHYR			
27.0		1077.5025	IVGGWECEK		+	-
		1407.7497	HSQPWQVLVASR			
		757.4919				
		1887.9398				
		1272.6685	LSEPAELTDAVK			
		870.395				
		<u>1383.6689</u>				
24.4			IVGGWECEK		-	-
			HSQPWQVLVASR			
			FLRPGDDSSHDLM*LLR			
			LSEPAELTDAVK			
23.0			IVGGWECEK		-	-
			HSQPWQVLVASR			
			FLRPGDDSSHDLM*LLR			
			LSEPAELTDAVK			
23	31.6	1077.5041	IVGGWECEK		<i>n.a.</i>	+
		1407.752	HSQPWQVLVASR			

		2344.228			
		757.493			
		3509.6858			
		1887.9423	FLRPGDDSSHDLM*LLR		
		1272.6703			
		2588.3118	KLQCVDLHVISNDVCAQVHPQK		
		2460.2179	LQCVDLHVISNDVCAQVHPQK		
		854.4012			
		870.3962			
		673.3773			
30.5		1407.7509		n.a.	-
		757.4924			
		1887.9413	FLRPGDDSSHDLM*LLR		
		1272.6699			
		2588.3131			
		870.3958			
24	31.6	1077.5028	IVGGWECEK	n.a.	+
		1407.7504	HSQPWQVLVASR		
		757.4918			
		1871.9447	FLRPGDDSSHDLMLLR		
		1272.6682	LSEPAELTDAVK		
		854.3999	FMLCAGR		
		870.3951			
		673.3763			
25	31.6	1077.5026	IVGGWECEK	n.a.	+
		1407.7506	HSQPWQVLVASR		
		757.4917			
		1871.945	FLRPGDDSSHDLMLLR		
		1887.94	FLRPGDDSSHDLM*LLR		
		1272.6684			
		2588.3076	KLQCVDLHVISNDVCAQVHPQK		
		2460.2092	LQCVDLHVISNDVCAQVHPQK		
		854.4003	FMLCAGR		
		870.3947			
27.0		1077.5008		n.a.	-
		1407.7481			
		757.4913			
		1871.9429			
		1272.6669			
		854.3987			
23.0		757.4918		n.a.	-
		1871.9455			
		1887.941			
		1272.6679			
21.8		1077.5022		n.a.	-
		1407.7497			
		757.4918			
		1871.9449			
		1272.668			

		854.3992			
26	31.6	1077.5034	IVGGWECEK	-	+
		1407.7511	HSQPWQVLVASR		
		757.4921			
		1871.9463	FLRPGDDSSHDLMLLR		
			FLRPGDDSSHDLM*LLR		
		1272.6695	LSEPAELTDAVK		
		2588.3121	KLQCVDLHVISNDVCAQVHPQK		
		2460.2148	LQCVDLHVISNDVCAQVHPQK		
		854.4006	FMLCAGR		
		870.3955			
		673.3765	VVHYR		
	23.0			+	-
27	31.6	1077.5012	IVGGWECEK	+	+
		1407.7483	HSQPWQVLVASR		
		757.4908			
		1887.9367	FLRPGDDSSHDLM*LLR		
		1272.6664	LSEPAELTDAVK		
		2588.2994	KLQCVDLHVISNDVCAQVHPQK		
		854.3988			
		870.3938			
		673.3756	VVHYR		
	30.5	1077.5016		-	-
		1407.7485			
		757.4908			
		1887.9357			
		1272.6664			
		870.3939			
		673.3756			
		854.3987			
	23.0			+	-
28	31.6	1077.5022	IVGGWECEK	n.a.	+
		1407.75	HSQPWQVLVASR		
			FLRPGDDSSHDLMLLR		
		1272.6682	LSEPAELTDAVK		
		854.3998			
		870.3945			
		673.3761			
	23.0			n.a.	-
29	31.6	1077.5026	IVGGWECEK	-	+
		1407.7501	HSQPWQVLVASR		
		2344.2222	AVCGGVLVHPQWVLTA AH		
		757.4922			
		1871.9466	FLRPGDDSSHDLMLLR		
		1887.941	FLRPGDDSSHDLM*LLR		
			LSEPAELTDAVK		
		2588.3099	KLQCVDLHVISNDVCAQVHPQK		
		2460.2155	LQCVDLHVISNDVCAQVHPQK		
		854.3998	FMLCARG		

		870.3949		
		673.3763	VVHYR	
31.6		1077.5016	IVGGWECEK	-
		1407.7491	HSQPWQVLVASR	-
		2344.2173	AVCGGVLVHPQWVLTAAH_CIR	
		757.491	SVILLGR	
		1871.9447	FLRPGDDSSHDLMLLR	
		1887.9396	FLRPGDDSSHDLM*LLR	
		1272.6666	LSEPAELTDAVK	
		2588.3069	KLQCVDLHVISNDVCAQVHPQK	
		2460.2128	LQCVDLHVISNDVCAQVHPQK	
		854.3994	FMLCARG	
		870.3943		
		673.3759	VVHYR	
27.0			IVGGWECEK	-
			HSQPWQVLVASR	-
			FLRPGDDSSHDLM*LLR	-
25.9				+
24.4		1077.5026	HSQPWQVLVASR	-
		1407.7497		-
		1272.6686		
		854.3996		
		870.3948		
		673.3764		
23.0		1077.5013	IVGGWECEK	-
		1407.7484	HSQPWQVLVASR	-
		757.4909		
		1887.9376	FLRPGDDSSHDLM*LLR	
		1272.6667	LSEPAELTDAVK	
21.8				-
C1	34.6	1077.5025		-
		1407.7496		+
		757.492		
		1887.9405		
		1272.6684		
		2588.3059		
		2460.2157		
		870.3951		
		854.4004		
		673.3766		
	33.1	1077.5021		-
		1407.7496		+
		757.4916		
		1887.9392		
		1272.6679		
		2588.3082	KLQCVDLHVISNDVCAQVHPQK	
		2460.2114		
		870.3946		
		673.3763		

	31.6	1077.5026	IVGGWECEK	-	+
		1407.75	HSQPWQVLVASR		
		757.4918	SVILLGR		
		1871.9372			
		1887.9401	FLRPGDDSSHDLM*LLR		
		1272.6682			
			KLQCVDLHVISNDVCAQVHPQK		
		2460.2143	LQCVDLHVISNDVCAQVHPQK		
		854.4004			
		870.395			
		673.3764	VVHYR		
	23.0			+	-
C2	31.6	1077.5039	IVGGWECEK	-	+
		1407.7518	HSQPWQVLVASR		
		2344.2238	AVCGGVLVHPQWVLTAAH_CIR		
		757.4924	SVILLGR		
		3493.693			
		3509.6916	HSLFHPEDTGQVFQVSHSFPHPPLYDSLK		
		1871.9477	FLRPGDDSSHDLMLLR		
		1887.943	FLRPGDDSSHDLM*LLR		
		1272.6697	LSEPAELTDAVK		
		3540.6517			
		2588.3118	KLQCVDLHVISNDVCAQVHPQK		
		2460.2184	LQCVDLHVISNDVCAQVHPQK		
		854.4007	FMLCAGR		
		870.3959			
			ALPERPSLY		
		673.3768	VVHYR		
	30.5	1077.504	IVGGWECEK	+	-
		1407.7516	HSQPWQVLVASR		
			AVCGGVLVHPQWVLTAAH		
		757.4928			
			FLRPGDDSSHDLMLLR		
		1887.9418	FLRPGDDSSHDLM*LLR		
		1272.6694	LSEPAELTDAVK		
			KLQCVDLHVISNDVCAQVHPQK		
		870.3961			
		673.3771	VVHYR		
	27.0		LQCVDLHVISNDVCAQVHPQK	-	-
	25.9		IVGGWECEK	+	-
			HSQPWQVLVASR		
			FLRPGDDSSHDLM*LLR		
			LSEPAELTDAVK		
	24.4	1077.504	IVGGWECEK	+	-
		1407.7524	HSQPWQVLVASR		
		2344.2264	AVCGGVLVHPQWVLTAAH		
		757.4927	SVILLGR		
		3509.6918			
		1887.943	FLRPGDDSSHDLM*LLR		

	23.0	1272.6694	LSEPAELTDAVK IVGGWECEK HSQPWQVLVASR	-	-
C3	40.0			-	-
	31.6	1077.505	IVGGWECEK	-	+
		1407.7534	HSQPWQVLVASR		
		2344.2247	AVCGGVLVHPQWVLTAAH		
		757.4934			
		3509.6967			
		1887.9445	FLRPGDDSSHDLMLLR		
		1272.6711	LSEPAELTDAVK		
		2588.3132	KLQCVDLHVISNDVCAQVHPQK		
		2460.2189	LQCVDLHVISNDVCAQVHPQK		
		854.4018			
		870.3968			
		673.3778	VVHYR		
	30.5	1077.5049	IVGGWECEK	-	-
		1407.7525	HSQPWQVLVASR		
		757.4936			
		1887.9441	FLRPGDDSSHDLMLLR		
		1272.6706			
		870.3968			
		673.3776	VVHYR		
C4	31.6	1077.5027	IVGGWECEK	<i>n.a.</i>	+
		1407.7503	HSQPWQVLVASR		
		2344.2205	AVCGGVLVHPQWVLTAAH_CIR		
		757.4915	SVILLGR		
		3509.6947			
			FLRPGDDSSHDLMLLR		
		1887.9413	FLRPGDDSSHDLMLLR		
		1272.668	LSEPAELTDAVK		
		2588.3095	KLQCVDLHVISNDVCAQVHPQK		
		2460.2152	LQCVDLHVISNDVCAQVHPQK		
		854.3999			
		870.3948			
		673.3761	VVHYR		
	30.5	1077.5023	IVGGWECEK	<i>n.a.</i>	-
		1407.7496	HSQPWQVLVASR		
		757.4914			
		1887.9397	FLRPGDDSSHDLMLLR		
		1272.6675	LSEPAELTDAVK		
		854.3998			
		870.3947			
		673.3761	VVHYR		
	23.0	1077.5025	IVGGWECEK	<i>n.a.</i>	-
		1407.7498	HSQPWQVLVASR		
		757.492			
		1272.6685	LSEPAELTDAVK		
		1887.9387	FLRPGDDSSHDLMLLR		

	21.8	1077.5019	IVGGWECEK	n.a.	-
		1407.7487	HSQPWQVLVASR		
		757.4913			
		1887.9382	FLRPGDDSSHDLMLLR		
		1272.667	LSEPAELTDAVK		
C5	40.0			n.a.	+
	33.1	1077.5005	IVGGWECEK	n.a.	+
		1407.7472	HSQPWQVLVASR		
		757.4904			
		1887.9363	FLRPGDDSSHDLMLLR		
		1272.6655	LSEPAELTDAVK		
		854.3981			
		870.3934			
		673.375	VVHYR		
	31.6	1077.5007	IVGGWECEK	n.a.	+
		1407.7475	HSQPWQVLVASR		
		757.4908	SVILLGR		
		1887.9365	FLRPGDDSSHDLMLLR		
		1272.6659	LSEPAELTDAVK		
		854.3985			
		870.3935			
		673.3752	VVHYR		